Nemaline myopathy with dilated cardiomyopathy and severe heart failure: A case report

Qian Wang, Fan Hu

ORCID number: Qian Wang 0000-0002-0382-9872; Fan Hu 0000-0002-2583-4058.

Author contributions: Wang Q and Hu F provided the concept for the study; Wang Q drafted the manuscript; Hu F performed the review; all authors have read and approved the content of the manuscript.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: We declare that we have no conflicts of interest related to this work.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially.

Abstract

BACKGROUND
Nemaline myopathy (NM) is a rare type of congenital myopathy, with an incidence of 1:50000. Patients with NM often exhibit hypomyotonia and varying degrees of muscle weakness. Skeletal muscles are always affected by this disease, while myocardial involvement is uncommon. However, with improvements in genetic testing technology, it has been found that NM with a mutation in the myopalladin (MYPN) gene not only causes slow, progressive muscle weakness but also results in dilated or hypertrophic cardiomyopathy.

CASE SUMMARY
A 3-year-old pre-school boy was admitted to our hospital with cough, edema, tachypnea, and an increased heart rate. The patient was clinically diagnosed with severe dilated cardiomyopathy and heart failure, and subsequent gene examination confirmed the diagnosis of NM with a mutation in MYPN. Captopril, diuretics, low-dose digoxin, and dobutamine were administered. After 22 d of hospitalization, the patient was discharged due to the improvement of clinical symptoms. During the follow-up period, the patient died of refractory heart failure.

CONCLUSION
Decreased muscular tone and dilated cardiomyopathy are common features of MYPN-mutated NM. Heart transplantation may be a solution to this type of cardiomyopathy.

Key Words: Nemaline myopathy; Myopalladin; Dilated cardiomyopathy; Heart failure; Whole-exome sequencing; Case report
Nemaline myopathy (NM) is a rare type of congenital myopathy, with an incidence of 1:50000\[^1\]. A distinct pathological characteristic of NM is the accumulation of “rod” shaped structures observed by light or electron microscopy\[^2\]. Patients with NM often have hypomyotonia and varying degrees of muscle weakness. Skeletal muscles are always affected by this disease, while myocardial involvement is uncommon. However, it has been recognized that NM with a mutation in the myopalladin (MYPN) gene not only causes slow, progressive muscle weakness but also results in dilated or hypertrophic cardiomyopathy\[^3\].

Here, we report the case of a 3-year-old boy with NM who was admitted with dilated cardiomyopathy and heart failure followed by genetic confirmation of NM with an MYPN mutation.

Citation: Wang Q, Hu F. Nemaline myopathy with dilated cardiomyopathy and severe heart failure: A case report. World J Clin Cases 2021; 9(11): 2569-2575
URL: https://www.wjgnet.com/2307-8960/full/v9/i11/2569.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i11.2569

INTRODUCTION

Nemaline myopathy (NM) is a rare type of congenital myopathy, with an incidence of 1:50000\[^1\]. A distinct pathological characteristic of NM is the accumulation of “rod” shaped structures observed by light or electron microscopy in muscle biopsies\[^2\]. Patients with NM often have hypomyotonia and varying degrees of muscle weakness. Skeletal muscles are always affected by this disease, while myocardial involvement is uncommon. However, with improvements in genetic testing technology, it has been recognized that NM with a mutation in the myopalladin (MYPN) gene not only causes slow, progressive muscle weakness but also results in dilated or hypertrophic cardiomyopathy\[^3\].

Here, we report the case of a 3-year-old boy with NM who was admitted with dilated cardiomyopathy and heart failure followed by the genetic confirmation of NM with an MYPN mutation. The ethics committee of the West China Second University Hospital of Sichuan University approved this study. Informed consent was obtained from the patient for publication of this case report.

CASE PRESENTATION

Chief complaints
A 3-year-old boy was referred to our hospital with cough, edema, tachypnea, and tachycardia.

History of present illness
One week before admission, the patient began to exhibit a paroxysm of coughing with phlegm, accompanied with fatigue and plummeting level of physical activity. Soon afterwards, he exhibited edema all over the body, particularly on the face and both lower limbs. Half a day before admission, the patient developed tachypnea and tachycardia.

History of past illness
It is worth noting that the patient had a history of delayed physical growth development. He only learned to sit when he was 10 mo old, and he still could not crawl or stand at 1 year of age. He was sent to a hospital and diagnosed with growth retardation. Doctors guided the boy in a rehabilitation training program for 1 year, after which he appeared to walk and run with no significant difference compared with his peers. However, the parents found that his muscle tension was low, and that he fell over easily. In addition, the patient had strephenopodia after birth, which improved after the use of orthotics.
Personal and family history
The family history was unremarkable.

Physical examination
When the patient was admitted to our hospital, he had symmetrical edema in the face and lower extremities. The pulmonary respiratory sounds were rough with a few coarse rales. There was no protuberance in the precordial region. The apical impulse of the heart was diffused. Heart amplification was identified, and the apical beat was at the sixth intercostal space, 4.5 cm outside the middle line of the left clavicle. Neither thrill nor pericardium friction was found. The heart rhythm was regular with a gallop rhythm and low cardiac sound. The abdomen was supple with the liver 4 cm below the costal margin and 6 cm below the xiphoid, with the spleen impalpable. Moreover, the boy had an elongated face, inhibited facial expressions, a high palate arch (Figure 1), clawfoot, normal muscular strength, decreased muscular tone, and decreased bilateral knee reflexes. The Gower’s sign was positive, and the meningeal irritation sign was negative.

Laboratory examinations
The serum cardiac troponin I level was 0.211 µg/L (normal < 0.034 µg/L). The level of brain natriuretic peptide reached up to 27500 pg/mL (normal < 215 pg/mL). The alanine aminotransferase level was 458 U/L (normal < 72 U/L), and aspartate aminotransferase level was 671 U/L (normal < 59 U/L). However, there was no significant increase in creatine kinase (99 U/L; normal < 170 U/L), creatine kinase myocardial band (2.29 μg/L; normal < 3.38 μg/L), and myoglobin (133.1 μg/L; normal < 121 μg/L).

Imaging examinations
After one week in the hospital, Holter showed about 16.6% of ventricular premature beats (VPBs) of the total number of beats (Figure 2). Echocardiogram showed that the patient had enlarged, weakened left and right ventricles with decreased systolic function. The heart chamber sizes were as follows: Left atrium, 27 mm (normal < 18 mm); left ventricle, 58 mm (normal < 31 mm); right atrium, 40 mm (normal < 32 mm); right ventricle, 22 mm (normal < 11 mm). The ejection fraction was 18%, and the fraction of shortening was 8%. The systolic excursion of the tricuspid annular plane was 13 mm (Figure 3). Cardiac magnetic resonance imaging showed enlarged ventricles, reduced systolic function, and focal delayed enhancement (Figure 4).

FINAL DIAGNOSIS
Based on the above findings, NM was suspected.

TREATMENT
Initially, we thought that the condition in question might be myocarditis or idiopathic cardiomyopathy. The patient received spironolactone (2 mg/kg), hydrochlorothiazide (2 mg/kg), captopril (1 mg/kg), and digoxin (6 μg/kg). In addition, intravenous methylprednisolone was administered for 3 d followed by oral prednisone for 4 d. The degree of heart failure appeared to be very severe, so dobutamine (6 μg/kg) was also administered on the day of admission. The edema and cough improved, with the disappearance of rales after 1 wk of treatment, and we stopped using dobutamine (Table 1).

We continued using spironolactone, hydrochlorothiazide, captopril, digoxin, and dobutamine (we stopped using dobutamine when the patient was in stable condition). After 22 d of treatment, the edema completely regressed and the gallop rhythm disappeared. The patient still exhibited sinus tachycardia with a reduced VPB of 8.9%. Echocardiography showed that the ejection fraction was 23% and the fraction of shortening was 11% after treatment.
Table 1 Summary of the clinical course

| Symptoms | Signs | Drug administration |
|----------|-------|---------------------|
| Edema    | Cough | Tachypnea | Tachycardia | Rale | Gallop rhythm | Rhythm | Hepatomegaly | |
| Day 1    | +     | ++        | ++          | +    | +             | +      | 4 cm below costal margin | Spironolactone, hydrochlorothiazide, captopril, digoxin, dobutamine, methylprednisolone |
| Day 4    | +     | ++        | ++          | +    | +             | +      | 4 cm below costal margin | Spironolactone, hydrochlorothiazide, captopril, digoxin, dobutamine, methylprednisolone |
| Day 8    | -     | -         | ++          | +    | -             | +      | 4 cm below costal margin | Spironolactone, hydrochlorothiazide, captopril, digoxin |
| Day 18   | -     | -         | +           | +    | -             | -      | 3 cm below costal margin | Spironolactone, hydrochlorothiazide, captopril, digoxin |
| Day 22   | -     | -         | +           | +    | -             | -      | 3 cm below costal margin | Spironolactone, hydrochlorothiazide, captopril, digoxin |

Figure 1 High palate arch of the patient: A typical sign of nemaline myopathy.

OUTCOME AND FOLLOW-UP

The patient was discharged due to improvement in heart failure symptoms. He continued to be administered with spironolactone, hydrochlorothiazide, captopril, and digoxin at home. During the follow-up period, the patient suffered from repeated and worsened heart failure and was hospitalized. Ultimately, he died of uncontrollable heart failure 4 mo after the first admission.

DISCUSSION

NM is a sporadic, rare congenital myopathy[4]. Genetic mutations that cause skeletal muscle involvement lead to this disease. Clinical manifestations vary in different patients. NM was divided into six types by the European Commission for Neuromuscular Diseases[5]: (1) Severe congenital NM. Patients exhibit clinical symptoms at birth, with feeding difficulties, hypotonia, myasthenia, respiratory failure, and no independent activities. Most patients die at an early stage, usually no more than one year of age; (2) Typical form of NM. This type has the highest incidence. Children get sick at an early age, with obvious muscle weakness in the face,
Figure 2 A total of 28352 ventricular premature beats in Holter monitoring. A: Four instances of paired ventricular premature beats; B: 2069 instances of ventricular bigeminy; C: 245 instances of ventricular trigeminy.

Figure 3 Echocardiogram. The heart chamber sizes showed an enlarged heart, especially the left heart.

medulla oblongata, and respiratory system. Muscle strength possibly increases with age. The quality of life in most patients is not affected. Patients have normal intelligence and myocardial contractility; (3) Intermediate congenital NM. This form has an onset in early infancy, spontaneous respiratory movement may occur at birth, but in early childhood. Patients may develop an inability to breathe autonomously, and walk and stand independently. Muscle contractures may occur during early childhood. The clinical symptoms of this type of NM are congenital severe syndromes and congenital mild syndromes; (4) Mild, childhood-, or juvenile-onset NM. The clinical manifestations are similar to mild syndromes, except that the onset age is late childhood or adolescence; (5) Adult form of NM. The age of onset is 30 to 60 years, and this form is incredibly diverse, with vast differences in clinical manifestations and disease progression. Cases are sporadic and have no family history. The onset is acute or subacute, and the respiratory muscles are easily involved. The disease has a quick
The presence of rod-like bodies is a characteristic change observed in muscle biopsies, and there are many eosinophilic rod-like structures under the myofilm or in the myoplasm\(^\text{[6-8]}\). However, due to various limitations, muscle biopsies are not easy to perform. Besides, with the development of genetic testing, muscle biopsies are no longer the only gold standard. Our patient did not undergo a muscle biopsy due to severe heart failure and refusal from the parents.

So far, at least 13 gene mutations have been recognized to be associated with NM, including \(\text{TPM3, NEB, ACTA1, TPM2, TNNT1, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYO18B, TNNT3, and MYPN}\)\(^\text{[3]}\). MYPN is a sarcoma component. It is generally found in the sarcomere, cardiac muscle, and skeletal muscle nucleus. The central regions and C-terminus of MYPN can bind to both α-actinin and nebulin in the skeletal muscle or nebulette in the cardiac muscle at the Z-line\(^{\text{[9]}\). On the other hand, its N-terminal region binds to cardiac ankyrin repeat protein\(^{\text{[10]}\). In an animal model, MYPN has been shown to potentially promote muscle growth\(^{\text{[11]}\). Patients with MYPN mutations show manifestations of myopathy and dilated or hypertrophic cardiomyopathy\(^{\text{[12,13]}\).

The patient in question had normal intelligence, but his motor developmental milestones were delayed after birth. In addition, the facial and skeletal characteristics, including an elongated face, high palate arch, and clawfoot, are typical signs of NM\(^{\text{[14,15]}\). Decreased muscular tone, a positive Gower’s sign, and dilated cardiomyopathy are common features of MYPN-mutated NM. The typical clinical manifestations and genetic tests supported the diagnosis. Unfortunately, the heart failure was too severe to be controlled by drugs. β-blockers are another treatment option for cardiomyopathy but the patient had such poor heart function that we did not use it after careful evaluation of the risk. Heart transplantation may be a solution to this type of cardiomyopathy.

CONCLUSION

In some cases, life-threatening cardiomyopathy with severe heart failure is a manifestation of inherited myopathy. When diagnosing cardiomyopathy, the development of striated muscles should be detected.
ACKNOWLEDGEMENTS

We thank all of the participants in this case report and people involved in diagnosis. We thank the Sichuan Province Science and Technology Support Program of China. We also thank the parents of the patient, who were always cooperative with our doctors.

REFERENCES

1 de Winter JM, Ottenheijm CAC. Sarcomere Dysfunction in Nemaline Myopathy. J Neuromuscul Dis 2017; 4: 99-113 [PMID: 28436394 DOI: 10.3233/JND-160200]

2 Cassandrini D, Trovato R, Rubegni A, Lenzi S, Fiorillo C, Baldacci J, Minetti C, Astrea G, Bruno C, Santorelli FM; Italian Network on Congenital Myopathies. Congenital myopathies: clinical phenotypes and new diagnostic tools. Ital J Pediatr 2017; 43: 101 [PMID: 29141652 DOI: 10.1186/s13052-017-0419-z]

3 Sewry CA, Laitlea JM, Wallgren-Pettersson C. Nemaline myopathies: a current view. J Muscle Res Cell Motil 2019; 40: 111-126 [PMID: 31228046 DOI: 10.1007/s13023-017-0640-2]

4 Yeşilbaş O, Şevketoğlu E, Kuhtir HS, Ersoy M, Petmezci MT, Akkuş CH, Şahin Ö, Ceylaner S. A rare structural myopathy: Nemaline myopathy. Turk Pediatr Ars 2019; 54: 49-52 [PMID: 31217710 DOI: 10.5152/TurkPediatr Ars.2018.440.2]

5 Wallgren-Pettersson C, Laing NG. Report of the 70th ENMC International Workshop: nemaline myopathy, 11-13 June 1999, Naarden, The Netherlands. Neuromuscular Disord 2000; 10: 299-306 [PMID: 10832258 DOI: 10.1016/S0960-8966(99)00129-7]

6 Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, Stenzel W, Rushing EJ, Van Damme P, Ferbert A, Petri S, Hartmann C, Bornemann A, Meisel A, Petersen JA, Tousseyn T, Thal DR, Reimann J, De Jonghe P, Martin JJ, Van den Bergh PY, Schulz JB, Weis J, Claes KG. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet J Rare Dis 2017; 12: 86 [PMID: 28490364 DOI: 10.1186/s13023-017-0640-2]

7 D’Amico A, Fattori F, Fiorillo C, Paglietti MG, Testa MBC, Verardo M, Catteruccia M, Bruno C, Bertini E. 'Amish Nemaline Myopathy' in 2 Italian siblings harbouring a novel homozygous mutation in Troponin-I gene. Neuromuscular Disord 2019; 29: 766-770 [PMID: 31604653 DOI: 10.1016/j.nmd.2019.02.005]

8 Sztal TE, Zhao M, Williams C, Oorschot V, Parslow AC, Giousoul A, Yuen M, Hall TE, Costin A, Ramg G, Bird PI, Busch-Nentwich EM, Stemple DL, Currie PD, Cooper ST, Laing NG, Nowak KJ, Bryson-Richardson RJ. Zebrafil models for nemaline myopathy reveal a spectrum of nemaline bodies contributing to reduced muscle function. Acta Neuropathol 2015; 130: 389-406 [PMID: 25931053 DOI: 10.1007/s00401-015-1430-3]

9 Miyatake S, Mitsushashi S, Hayashi YK, Purejav E, Nishikawa A, Koshimizu E, Suzuki M, Yatabe K, Tanaka Y, Ogata K, Kuru S, Shimna M, Tsursukai Y, Nakashima M, Mizuguchi T, Miyaake N, Saito H, Ogata K, Kawai M, Towbin J, Nonaka I, Nishino I, Matsumoto N. Biallelic Mutations in MYPN, Encoding Myopalladin, Are Associated with Childhood-Onset, Slowly Progressive Nemaline Myopathy. Am J Hum Genet 2017; 100: 169-178 [PMID: 28017374 DOI: 10.1016/j.ajhg.2016.11.017]

10 Bang ML, Mudry RE, McElhinny AS, Trombitas K, Geach AJ, Yamasaki R, Sorimachi H, Granzer G, Gregorio CC, Labeit S. Myopalladin, a novel 145-kilodalton sarcomeric protein with multiple roles in Z-disc and I-band protein assemblies. J Cell Biol 2019; 213: 169-178 [PMID: 29817374 DOI: 10.1083/jcb.201902011]

11 Merlini L, Sabatelli P, Antonioli M, Carinci V, Niro F, Monetti G, Torella A, Giugliano T, Faldini C, Nigro V. Congenital myopathy with hanging big toe due to homozygous myopalladin (MYPN) mutation. Skelet Muscle 2019; 9: 14 [PMID: 31133047 DOI: 10.1186/s13395-019-0199-9]

12 Zhao Y, Feng Y, Zhang YM, Ding XX, Song YZ, Zhang AM, Liu L, Zhang H, Ding JH, Xia XS. Targeted next-generation sequencing of candidate genes reveals novel mutations in patients with dilated cardiomyopathy. Int J Mol Med 2015; 36: 1479-1486 [PMID: 26458567 DOI: 10.3892/ijmm.2015.2361]

13 Chen Y, Barajas-Martinez H, Zhu D, Wang X, Chen C, Zhuang B, Shi J, Wu X, Tao Y, Jin W, Wang X, Hu D. Erratum to: Novel trigenic CACNA1C/DES/MYPN mutations in a family of hypertrophic cardiomyopathy with early repolarization and short QT syndrome. J Transl Med 2017; 15: 101 [PMID: 28490369 DOI: 10.1186/s12967-017-1203-y]

14 Xue Y, Magoulas PL, Wirthlin JO, Buchanan EP. Craniofacial Manifestations in Severe Nemaline Myopathy. J Craniofac Surg 2017; 28: e258-e260 [PMID: 28468212 DOI: 10.1097/SCS.0000000000002483]

15 Yeung KS, Yu FY, Fung CW, Wong S, Lee HH, Fung STH, Fung GPG, Leung KY, Chung WH, Lee YT, Ng VKS, Yu MHC, Fung JLF, Tsang MHY, Chan KYK, Chan SHS, Kan ASY, Chung BHY. The KHLR40 c.1516A> C is a Chinese-specific founder mutation causing nemaline myopathy 8: Report of six patients with pre- and postnatal phenotypes. Mol Genet Genomic Med 2020; 8: e1229 [PMID: 32352246 DOI: 10.1002/mgg3.1229]
